Table 2. Effects of anti-GR-1... | American Society of Hematology

Table 2.

Effects of anti-GR-1 administration on femur and spleen nucleated cellularity and total CFU-GM per organ

	TNC/femur × 10⁶*			CFU-GM/femur × 10⁴*			TNC/spleen × 10⁶†
Mobilizer	Isotype	Anti-GR-1	Isotype	Anti-GR-1	Isotype	Anti-GR-1	Isotype	Anti-GR-1
PBS	12.3 ± 0.9	9.2 ± 0.6‡	3.6 ± 0.3	3.1 ± 0.2	110 ± 6.9	112 ± 20.4	1.0 ± 0.3	1.0 ± 0.4
GROβ	12.7 ± 0.6	9.2 ± 0.8§	3.7 ± 0.4	3.1 ± 0.2	109 ± 13.3	103 ± 4.4	0.7 ± 0.2	1.0 ± 0.3
GROβ_T (SB25 1353)	11.9 ± 0.8	9.4 ± 0.6§	3.9 ± 0.3	3.3 ± 0.3	112 ± 18.4	109 ± 6.2	0.6 ± 0.4	1.0 ± 0.2
G-CSF	12.2 ± 1.2	7.5 ± 0.4§	3.8 ± 0.4	3.4 ± 0.1	169 ± 6.2∥	150 ± 12.8	10.4 ± 0.9§	2.3 ± 0.4‡
G-CSF + GROβ	11.8 ± 1.1	8.2 ± 0.4¶	4.2 ± 0.7	3.4 ± 0.4	156 ± 17.2	150 ± 32.5	12.4 ± 2.1	2.7 ± 0.6‡
G-CSF + GROβ_T	12.7 ± 1.6	7.6 ± 0.3¶	4.5 ± 1.2	3.7 ± 0.5	163 ± 12.5	162 ± 29.7	11.7 ± 3.2	2.4 ± 0.7‡

	TNC/femur × 10⁶*			CFU-GM/femur × 10⁴*			TNC/spleen × 10⁶†
Mobilizer	Isotype	Anti-GR-1	Isotype	Anti-GR-1	Isotype	Anti-GR-1	Isotype	Anti-GR-1
PBS	12.3 ± 0.9	9.2 ± 0.6‡	3.6 ± 0.3	3.1 ± 0.2	110 ± 6.9	112 ± 20.4	1.0 ± 0.3	1.0 ± 0.4
GROβ	12.7 ± 0.6	9.2 ± 0.8§	3.7 ± 0.4	3.1 ± 0.2	109 ± 13.3	103 ± 4.4	0.7 ± 0.2	1.0 ± 0.3
GROβ_T (SB25 1353)	11.9 ± 0.8	9.4 ± 0.6§	3.9 ± 0.3	3.3 ± 0.3	112 ± 18.4	109 ± 6.2	0.6 ± 0.4	1.0 ± 0.2
G-CSF	12.2 ± 1.2	7.5 ± 0.4§	3.8 ± 0.4	3.4 ± 0.1	169 ± 6.2∥	150 ± 12.8	10.4 ± 0.9§	2.3 ± 0.4‡
G-CSF + GROβ	11.8 ± 1.1	8.2 ± 0.4¶	4.2 ± 0.7	3.4 ± 0.4	156 ± 17.2	150 ± 32.5	12.4 ± 2.1	2.7 ± 0.6‡
G-CSF + GROβ_T	12.7 ± 1.6	7.6 ± 0.3¶	4.5 ± 1.2	3.7 ± 0.5	163 ± 12.5	162 ± 29.7	11.7 ± 3.2	2.4 ± 0.7‡

Mice received anti-GR-1 or rat antimouse IgG2b isotype control mAb as described in Table 1.

Data from 4 experiments.

Data from 2 experiments.

P < .05.

P < .001.

P < .005.

P < .01.